FibroBiologics Files S-1/A Amendment

TL;DR

<b>FibroBiologics, Inc. has filed an S-1/A amendment detailing its financial structure and historical data.</b>

AI Summary

FibroBiologics, Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on March 26, 2024. FibroBiologics, Inc. filed an S-1/A amendment on March 26, 2024. The company is incorporated in Delaware with its fiscal year ending December 31. FibroBiologics is in the Pharmaceutical Preparations industry (SIC 2834). The filing includes data for fiscal years ending December 31, 2021, 2022, and 2023. Key financial data points such as preferred stock, common stock, additional paid-in capital, and retained earnings are detailed for these periods.

Why It Matters

For investors and stakeholders tracking FibroBiologics, Inc., this filing contains several important signals. This S-1/A filing is a crucial step for FibroBiologics as it prepares for potential public offering or significant corporate actions, providing transparency to investors. The detailed breakdown of preferred and common stock, along with capital accounts, offers insight into the company's capitalization and historical funding.

Risk Assessment

Risk Level: low — FibroBiologics, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, indicating ongoing regulatory processes rather than immediate financial distress or significant new risks.

Analyst Insight

Monitor future filings for updates on the company's offering status and financial performance.

Key Numbers

• 2024-03-26 — Filing Date (S-1/A filing date)
• 2023-12-31 — Fiscal Year End (Most recent fiscal year end reported)
• 2022-12-31 — Previous Fiscal Year End (Previous fiscal year end reported)
• 2021-12-31 — Prior Fiscal Year End (Prior fiscal year end reported)

Key Players & Entities

• FibroBiologics, Inc. (company) — Filer name
• 0001493152-24-011358 (filing_id) — Accession Number
• 20240326 (date) — Filing Date
• 2834 (industry_code) — Standard Industrial Classification
• DE (state) — State of Incorporation
• 1231 (fiscal_year_end) — Fiscal Year End
• FBLG (ticker) — Ticker Symbol

FAQ

Industry Context

FibroBiologics operates within the Pharmaceutical Preparations industry, focusing on the development and commercialization of biologic products.

Regulatory Implications

The S-1/A filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial statements and risk factors.
2. Track future SEC filings for updates on the company's progress and potential public offering.
3. Research the company's specific therapeutic areas and drug pipeline.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updates or additions to the initial registration statement.

Key Financial Figures

• $15.00 — aw-down threshold price of no less than $15.00 per share. GEM submitted two closing no
• $13.50 — ed in two tranches under the GEM SPA at $13.50 per share, for net cash proceeds of app
• $1.9 million — for net cash proceeds of approximately $1.9 million. We then authorized a reduction of the
• $12.15 — re purchased pursuant to the GEM SPA at $12.15 per share for net cash proceeds of appr
• $1.0 million — for net cash proceeds of approximately $1.0 million. The price per share that we receive pu
• $700,000,000 b — (ii) the quotient obtained by dividing $700,000,000 by the total number of equity interests.
• $21.54 — rants with an initial exercise price of $21.54 per share to GYBL. GEM and GYBL are un

Filing Documents

• forms-1a.htm (S-1/A) — 2532KB
• ex23-2.htm (EX-23.2) — 5KB
• forms-1a_001.jpg (GRAPHIC) — 4KB
• forms1-a_002.jpg (GRAPHIC) — 18KB
• forms-1a_003.jpg (GRAPHIC) — 18KB
• forms-1a_004.jpg (GRAPHIC) — 6KB
• forms-1a_005.jpg (GRAPHIC) — 7KB
• forms-1a_006.jpg (GRAPHIC) — 18KB
• forms-1a_007.jpg (GRAPHIC) — 15KB
• forms-1a_008.jpg (GRAPHIC) — 11KB
• forms-1a_009.jpg (GRAPHIC) — 12KB
• 0001493152-24-011358.txt (&nbsp;) — 7056KB
• fblg-20231231.xsd (EX-101.SCH) — 43KB
• fblg-20231231_cal.xml (EX-101.CAL) — 59KB
• fblg-20231231_def.xml (EX-101.DEF) — 194KB
• fblg-20231231_lab.xml (EX-101.LAB) — 340KB
• fblg-20231231_pre.xml (EX-101.PRE) — 273KB
• forms-1a_htm.xml (XML) — 614KB

RISK FACTORS

RISK FACTORS 9 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 60 MARKET AND INDUSTRY DATA 61 TRADEMARKS, SERVICE MARKS AND TRADENAMES 62

USE OF PROCEEDS

USE OF PROCEEDS 63 DIVIDEND POLICY 63 CAPITALIZATION 63

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 64

BUSINESS

BUSINESS 75 MANAGEMENT 99 EXECUTIVE AND DIRECTOR COMPENSATION 106 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 111 PRINCIPAL AND REGISTERED STOCKHOLDERS 112

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 114 SHARES ELIGIBLE FOR FUTURE SALE 118 SALE PRICE HISTORY OF OUR CAPITAL STOCK 119 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 119 PLAN OF DISTRIBUTION 12 4 LEGAL MATTERS 125 EXPERTS 125 WHERE YOU CAN FIND ADDITIONAL INFORMATION 12 5 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor any of the Registered Stockholders have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor any of the Registered Stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Registered Stockholders are offering to sell, and seeking offers to buy, shares of their common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor any of the Registered Stockholders have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by the Registered Stock

View Full Filing

View this S-1/A filing on SEC EDGAR